General Information of Drug (ID: DM6OEHK)

Drug Name
PMID25980951-Compound-22 Drug Info
Cross-matching ID
PubChem CID
53239649
TTD Drug ID
DM6OEHK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AT-406 DMVJW0S Squamous head and neck cell carcinom 2D60.0 Phase 3 [2]
Birinapant DM6PBUM Lymphoma 2A80-2A86 Phase 2 [3]
Phenoxodiol DMBUJVX Ovarian cancer 2C73 Phase 1/2 [4]
APG-1387 DMLEKUY Haematological malignancy 2B33.Y Phase 1 [5]
HGS-1029 DMS9WXG Haematological malignancy 2B33.Y Phase 1 [6]
GDC-0152 DM1B3UM Obesity 5B81 Phase 1 [7]
PMID25980951-Compound-6 DMVSW5N N. A. N. A. Patented [1]
PMID25980951-Compound-27 DMXAH9F N. A. N. A. Patented [1]
PMID25980951-Compound-43 DMTJRCS N. A. N. A. Patented [1]
PMID25980951-Compound-1 DMYPT2H N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AT-406 DMVJW0S Squamous head and neck cell carcinom 2D60.0 Phase 3 [2]
Birinapant DM6PBUM Lymphoma 2A80-2A86 Phase 2 [3]
PMID25980951-Compound-6 DMVSW5N N. A. N. A. Patented [1]
PMID25980951-Compound-27 DMXAH9F N. A. N. A. Patented [1]
PMID25980951-Compound-43 DMTJRCS N. A. N. A. Patented [1]
PMID25980951-Compound-1 DMYPT2H N. A. N. A. Patented [1]
PMID25980951-Compound-44 DMS5896 N. A. N. A. Patented [1]
PMID25980951-Compound-3 DMPSWXU N. A. N. A. Patented [1]
PMID25980951-Compound-4 DM9RZSH N. A. N. A. Patented [1]
PMID25980951-Compound-21 DMIE0MR N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cellular inhibitor of apoptosis 1 (BIRC2) TTQ5LRD BIRC2_HUMAN Antagonist [1]
X-linked inhibitor of apoptosis protein (XIAP) TTR7B60 XIAP_HUMAN Antagonist [1]

References

1 Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
2 Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51.
3 cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72.
4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5 XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.Theranostics. 2018 Feb 5;8(6):1494-1510.
6 Clinical pipeline report, company report or official report of Aegera Therapeutics Inc.
7 Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012 May 10;55(9):4101-13.